Home » Stocks » TLSA

Tiziana Life Sciences PLC (TLSA)

Stock Price: $2.87 USD 0.07 (2.50%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 274.31M
Revenue (ttm) n/a
Net Income (ttm) -9.32M
Shares Out 136.46M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $2.87
Previous Close $2.80
Change ($) 0.07
Change (%) 2.50%
Day's Open 2.76
Day's Range 2.61 - 2.94
Day's Volume 234,530
52-Week Range 0.62 - 12.17

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

NEW YORK and LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, a...

Proactive Investors - 2 weeks ago

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said it is presenting at the BIO CEO & Investor Digital Conference. The conference starts today and runs until Thursday.

GlobeNewsWire - 2 weeks ago

NEW YORK and LONDON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeu...

Proactive Investors - 3 weeks ago

Iconic Labs PLC (LON:ICON), a multidivisional new media and technology business, announced that it has appointed Sarah Dees as its chief executive officer and an executive director with immedi...

Other stocks mentioned: SLN
GlobeNewsWire - 1 month ago

NEW YORK and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeu...

Zacks Investment Research - 1 month ago

Tiziana (TLSA) reports positive data from a study investigating its anti-CD3 human monoclonal antibody, foralumab (nasally administered) for treating COVID-19 patients in Brazil. Shares up.

GlobeNewsWire - 1 month ago

NEW YORK and LONDON, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA/LSE:TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics...

Benzinga - 1 month ago

GlobeNewsWire - 1 month ago

NEW YORK and LONDON, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeu...

GlobeNewsWire - 1 month ago

NEW YORK and LONDON, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammati...

GlobeNewsWire - 1 month ago

NEW YORK and LONDON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeu...

GlobeNewsWire - 1 month ago

NEW YORK and LONDON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeu...

GlobeNewsWire - 1 month ago

NEW YORK and LONDON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeu...

GlobeNewsWire - 1 month ago

NEW YORK and LONDON, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeu...

GlobeNewsWire - 1 month ago

NEW YORK and LONDON, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeu...

GlobeNewsWire - 2 months ago

NEW YORK and LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeu...

GlobeNewsWire - 2 months ago

This announcement is an advertisement and not a prospectus. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or ...

GlobeNewsWire - 2 months ago

LONDON and NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeu...

GlobeNewsWire - 3 months ago

NEW YORK and LONDON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for onc...

GlobeNewsWire - 3 months ago

LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeu...

GlobeNewsWire - 3 months ago

First Ever Study with take-home capsules of Foralumab , a Fully Human Anti-CD3 Monoclonal Antibody

Bloomberg Markets and Finance - 4 months ago

Tiziana Enters Human Trials for Covid-19 Treatment

Nov.02 -- Tiziana Life Sciences PLC is launching a clinical trial in Brazil involving humans where they will be treated with a nasally administered Foralumab, a monoclonal antibody. Gabriele C...

GlobeNewsWire - 4 months ago

Tiziana Life Sciences plc

GlobeNewsWire - 4 months ago

NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeu...

Zacks Investment Research - 4 months ago

As of late, it has definitely been a great time to be an investor in Tiziana Life Sciences (TLSA).

GlobeNewsWire - 5 months ago

LONDON, Oct. 02, 2020 (GLOBE NEWSWIRE) -- At the General Meeting of the Company (Nasdaq: TLSA / AIM: TILS) held at 11.00 a.m. on 2 October 2020, both of the resolutions were duly passed.

GlobeNewsWire - 5 months ago

LONDON and NEW YORK, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative thera...

GlobeNewsWire - 5 months ago

LONDON and NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), is pleased to note the publication of a new analyst...

GlobeNewsWire - 5 months ago

Nasal Administration of Foralumab is a potentially transformative approach for treating patients with Covid-19

GlobeNewsWire - 5 months ago

Tiziana Shareholders to receive 1:1 share dividend in Accustem Sciences Tiziana Shareholders to receive 1:1 share dividend in Accustem Sciences

GlobeNewsWire - 5 months ago

Proposed capital reduction and notice of General Meeting Proposed capital reduction and notice of General Meeting

GlobeNewsWire - 6 months ago

ADS Registration Statement filed in order to Increase Capacity under the ADS Facility to Exchange Ordinary Shares for ADSs ADS Registration Statement filed in order to Increase Capacity under ...

GlobeNewsWire - 6 months ago

NEW YORK and LONDON, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing ta...

GlobeNewsWire - 6 months ago

NEW YORK and LONDON, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therape...

GlobeNewsWire - 6 months ago

NEW YORK and LONDON, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therape...

GlobeNewsWire - 6 months ago

-          Dr. Ferrara is the discoverer of Avastin® and Lucentis®, multi-billion dollars antibody drugs from Genentech

GlobeNewsWire - 6 months ago

NEW YORK and LONDON, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therape...

GlobeNewsWire - 6 months ago

NEW YORK and LONDON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing ta...

GlobeNewsWire - 7 months ago

LONDON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a biotechnology company focused on innovative therapeutics for on...

GlobeNewsWire - 7 months ago

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

GlobeNewsWire - 7 months ago

NEW YORK and LONDON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the "Company" or "Tiziana"), a biotechnology company focused on innovative therape...

Benzinga - 7 months ago

Tiziana Life Sciences (NASDAQ: TLSA) shares are trading higher on Friday after news emerged the company has submitted a patent application covering the potential use of a nasally-administered ...

GlobeNewsWire - 7 months ago

LONDON and NEW YORK, July 31, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on th...

GlobeNewsWire - 7 months ago

NEW YORK and LONDON, July 31, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therap...

GlobeNewsWire - 7 months ago

NEW YORK and LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc the dual listed (NASDAQ:TLSA & UK AIMS:TILS) today announces its intention to apply for admission to listing ...

GlobeNewsWire - 7 months ago

NEW YORK and LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therap...

GlobeNewsWire - 7 months ago

LONDON and NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therap...

GlobeNewsWire - 7 months ago

NEW YORK and LONDON, July 20, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a US and UK biotechnology company that focuses on the discovery and development o...

Bloomberg Technology - 7 months ago

Tiziana CEO Says Don't Confuse Them With Tesla

Tiziana Life Sciences Plc is a dual-listed British biotech firm, says it's ridiculous to think investors confuse his company's ticker symbol with that of Tesla.

GlobeNewsWire - 7 months ago

LONDON and NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on th...

About TLSA

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), whi... [Read more...]

Industry
Biotechnology
IPO Date
Mar 24, 2000
CEO
Shailubhai Kunwar
Employees
8
Stock Exchange
NASDAQ
Ticker Symbol
TLSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for TLSA stock is "Buy." The 12-month stock price forecast is 9.50, which is an increase of 231.01% from the latest price.

Price Target
$9.50
(231.01% upside)
Analyst Consensus: Buy